BCYC adds 1,300,000 shares to 2020 Equity Incentive Plan (S-8)

Rhea-AI Filing Summary

Bicycle Therapeutics plc filed a Form S-8 to register an additional 1,300,000 ordinary shares, nominal value £0.01 per share, for issuance under the Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan. The increase is pursuant to Amendment No. 1 to the 2020 Plan and was filed under General Instruction E, adding to previously registered plan shares.

As filed with the Securities and Exchange Commission on October 30, 2025.

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 

Bicycle Therapeutics plc 

(Exact name of registrant as specified in its charter)

England and Wales (State or other jurisdiction of incorporation or organization)	Not applicable (I.R.S. Employer Identification No.)
Blocks A & B, Portway Building Granta Park Great Abington, Cambridge United Kingdom (Address of Principal Executive Offices)	CB21 6GS (Zip Code)

Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan 

(Full title of the plan)

Alethia Young 

Chief Financial Officer 

Bicycle Therapeutics Inc. 

35 Cambridgepark Drive, Suite 350 

Cambridge, MA 02140 

(Name and address of agent for service)

(617) 945-8155 

(Telephone number, including area code, of agent for service)

Copy to:

Laura A. Berezin 

Jaime L. Chase 

Cooley LLP 

1700 7th Avenue 

Seattle, WA 98101

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E

Pursuant to General Instruction E of Form S-8, Bicycle Therapeutics plc (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 1,300,000 ordinary shares, nominal value £0.01 per share (the “Ordinary Shares”), of the Registrant under the Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to Amendment No. 1 to the 2020 Plan, which authorizes an additional 1,300,000 shares for issuance under the 2020 Plan. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission are incorporated herein by reference:

(a)           the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on August 5, 2020 (File No. 333-240993), March 11, 2021 (File No. 333-254163), March 1, 2022 (File No. 333-263156), February 28, 2023 (File No. 333-270091), February 20, 2024 (File No. 333-277171), and February 25, 2025 (File No. 333-285197);

(b)           the Registrant’s Annual Report on Form 10-K (File No. 001-38916) for the fiscal year ended December 31, 2024, filed with the Commission on February 25, 2025 (the “Annual Report”);

(c)           the Registrant’s Quarterly Reports on Form 10-Q (File No. 001-38916) for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the Commission on May 1, 2025, August 8, 2025, and October 30, 2025, respectively;

(d)           the Registrant’s Definitive Proxy Statement (File No. 001-38916) filed with the Commission on April 23, 2025 (excluding those portions that are not incorporated by reference into the Annual Report);

(e)           the Registrant’s Current Reports on Form 8-K (File No. 001-38916) filed with the Commission on January 13, 2025, March 14, 2025, March 27, 2025, June 17, 2025, August 8, 2025, and September 8, 2025 (in each case, except for information contained therein which is furnished rather than filed); and

(f)            the description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-38916) filed with the Commission on May 20, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.6 to the Annual Report.

All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for documents or information deemed furnished and not filed in accordance with the rules of the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

1 

Item 8. Exhibits.

Exhibit  Number		Exhibit Description
3.1		Articles of Association, dated May 16, 2024 (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Commission on August 6, 2024).
4.1		Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-231076), filed with the Commission on May 13, 2019).
4.2		Form of American Depositary Receipt (included in Exhibit 4.1) (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-231076), filed with the Commission on May 13, 2019).
5.1		Opinion of Cooley (UK) LLP.
23.1		Consent of PricewaterhouseCoopers LLP.
23.3		Consent of Cooley (UK) LLP (included in Exhibit 5.1).
24.1		Power of Attorney (included on the signature page to this Registration Statement).
99.1		Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-38916), filed with the Commission on February 28, 2023).
99.2		Amendment No. 1 to the 2020 Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Commission on August 8, 2025).
107		Filing Fee Table

2 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, United Kingdom, on October 30, 2025.

	BICYCLE THERAPEUTICS PLC
	Name:	/s/ Kevin Lee
		Kevin Lee, Ph.D., MBA
		Chief Executive Officer

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned officers and directors of Bicycle Therapeutics plc, hereby severally constitute and appoint Kevin Lee and Alethia Young, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Bicycle Therapeutics plc and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities on October 30, 2025.

Name		Title
/s/ Kevin Lee		Chief Executive Officer and Director
Kevin Lee, Ph.D., MBA		(Principal Executive Officer)
/s/ Alethia Young		Chief Financial Officer
Alethia Young		(Principal Financial Officer)
/s/ Travis Thompson		Chief Accounting Officer
Travis Thompson		(Principal Accounting Officer)
/s/ Felix J. Baker		Chairman of the Board and Director
Felix J. Baker, Ph.D.
/s/ Janice Bourque		Director
Janice Bourque, MBA
/s/ Roger Dansey		Director
Roger Dansey, M.D.
/s/ Jose-Carlos Gutiérrez-Ramos		Director
Jose-Carlos Gutiérrez-Ramos, Ph.D.

3 

Name		Title
/s/ Hervé Hoppenot		Director
Hervé Hoppenot
/s/ Alessandro Riva		Director
Alessandro Riva, MD
/s/ Stephen Sands		Director
Stephen Sands, MBA
/s/ Charles Swanton		Director
Charles Swanton, MD, PhD
/s/ Gregory Winter		Director
Sir Gregory Winter, FRS
/s/ Alethia Young		Authorized Representative in the United States
Alethia Young

4 

FAQ

How many additional shares did Bicycle Therapeutics (BCYC) register on this S-8?

The filing registers an additional 1,300,000 ordinary shares.

What plan are the newly registered BCYC shares tied to?

They are for issuance under the Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan.

What authorizes the increase in BCYC plan shares?

The increase is pursuant to Amendment No. 1 to the 2020 Equity Incentive Plan.

What form did BCYC use to register these shares?

Bicycle Therapeutics used Form S-8 under General Instruction E to register additional plan shares.

What is the nominal value of the BCYC ordinary shares registered?

Each ordinary share has a £0.01 nominal value.

When was the S-8 signed for Bicycle Therapeutics?

The registration statement was signed on October 30, 2025.